{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-209745","form_type":"8-K","ticker":"ACRV","cik":"0001781174","company_name":"Acrivon Therapeutics, Inc.","filed_at":"2023-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.204989+00:00","generated_at":"2026-06-11T14:55:57.910226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Acrivon posts Q2 2023 net loss of $13.9M; cash $151M funds ops into 2025","bullets":["Net loss $13.9M vs $5.8M in Q2 2022; R&D expenses $10.5M, up from $4.1M.","Cash, equivalents and marketable securities $151.0M as of June 30, 2023.","Registrational-intent Phase 2 trial of ACR-368 enrolling; initial data expected H2 2023.","FDA granted two Fast Track designations for ACR-368 in OncoSignature-positive ovarian and endometrial cancers.","Appointed Charles Baum to board and Adam Levy as SVP IR and corporate affairs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-209745","json":"https://secwatch.observer/filing/0001193125-23-209745.json","markdown":"https://secwatch.observer/filing/0001193125-23-209745.md","text":"https://secwatch.observer/filing/0001193125-23-209745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/0001193125-23-209745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/d337383d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T14:55:57.910226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59d4902da22314ed09fc135a6a6df714eb9ea837","claim":"Acrivon Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $13.9 million.","evidence_excerpt":"Net loss for the quarter ended June 30, 2023 was $13.9 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1781174/000119312523209745/0001193125-23-209745-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the second quarter ended June 30, 2023"},{"label":"Net income","value":"$13.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}